Inventiva S.A. and Hepalys Pharma Inc. have entered into an exclusive licensing agreement to develop and commercialize Inventiva's proprietary drug candidate lanifibranor for the treatment of non-alcoholic steatohepatitis (NASH) in Japan and South Korea. Under the terms of this licensing agreement, Inventiva will receive a $10 million upfront payment, and is eligible to receive up to $231 million in milestone payments if certain clinical, regulatory and commercial conditions are met.